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ABSTRACT
The ability to introduce genetic modifications in the germ line of complex organisms has been a long-standing
goal of those who study developmental biology. In this regard, the mouse, a favorite model for the study of the
mammals, is unique: indeed not only is it possible since the late seventies, to add genes to the mouse genome
like in several other complex organisms but also to perform gene replacement and modification. This has
been made possible via two technological breakthroughs: 1) the isolation and culture of embryonic stem cells
(ES), which have the unique ability to colonize all the tissues of an host embryo including its germ line; 2)
the development of methods allowing homologous recombination between an incoming DNA and its cognate
chromosomal sequence (gene ‘‘targeting’’). As a result, it has become possible to create mice bearing null
mutations in any cloned gene (knock-out mice). Such a possibility has revolutionized the genetic approach of
almost all aspects of the biology of the mouse. In recent years, the scope of gene targeting has been widened
even more, due to the refinement of the knock-out technology: other types of genetic modifications may now
be created, including subtle mutations (point mutations, micro deletions or insertions, etc.) and chromosomal
rearrangements such as large deletions, duplications and translocations. Finally, methods have been devised
which permit the creation of conditional mutations, allowing the study of gene function throughout the life
of an animal, when gene inactivation entails embryonic lethality. In this paper, we present an overview of
the methods and scenarios used for the programmed modification of mouse genome, and we underline their
enormous interest for the study of mammalian biology.
Key words: embryonic stem cells (ES), genome, gene ‘‘targeting’’, knock-out mice, conditional mutations.
INTRODUCTION
For decades geneticists have understood the inter-
est of studying mutations that, through the geno-
type they generate, reveal the function of the genes
in which they are produced. However, in complex
organisms such as the mouse, which is a model of
choice for the study of mammals, for many years the
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mutations obtained were limited to those observed
randomly during breeding and were essentially vis-
ible modifications in phenotype (color of the fur,
morphology, behavior, etc.), and few developmen-
tal mutations were observed in this way. Therefore
the possibility of creating deliberate and controlled
genetic modifications was a dream anticipated by
Avery et al. (1944), more than fifty years ago. In
their seminal study using bacteria, these authors
demonstrated that DNA is the chemical support for
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hereditary characters: ‘‘Biologists have long
attempted by chemical means to induce in higher
organisms predictable and specific changes which
thereafter could be transmitted in series as heredi-
tary characters’’. The aim of our paper is to show
how this dream has become reality over the past
twenty years, through the development of methods
that modify the genetic make-up of the mouse (see
Table I). The creation of mice with genetic modifi-
cations programmed by the investigator has revolu-
tionized the study of almost all the biological aspects
of this animal and its various systems (immune, ner-
vous, hematopoietic, etc.) (for a review, see Capec-
chi 1989). Moreover, this could lead to the cre-
ation of murine models for human genetic diseases
(Smithies 1993), precious for studying their phys-
iopathology and eventually for the development of
appropriate therapies. As we will see later, this was
made possible by the breakthrough of two different
approaches: one led to the isolation in vitro of re-
markable cells: embryonic stem (ES) cells (Gardner
and Brook 1997); the other permitted identification,
in higher eukaryote cells, of the conditions required
for homologous recombination between incoming
DNA and the homologous sequence in the chromo-
some (Smithies et al. 1985, Wong and Capecchi
1986).
EMBRYONIC STEM CELLS: FABULOUS VEHICLES
FOR THE CREATION OF MUTANT MICE
In 1981, two laboratories reported the isola-
tion, from the culture of early mouse embryos, of
cell lines with the properties of pluripotent embry-
onic cells (Martin 1981, Evans and Kaufman 1981)
(see Table II). These cells, called Embryonic Stem
(ES) cells, after injection into a young embryo were
capable of colonizing all its tissues including the
germ line, thus giving birth to chimeras. The ES cell
genotype cells could then be ‘‘recycled’’ in vivo and
transmitted to future generations. Following this, it
was demonstrated that these cells could be geneti-
cally modified in vitro, by introduction of a trans-
gene, for example, but also that the corresponding
transgenic mice could be obtained (Gossler et al.
1986, Robertson et al. 1986) (see Fig. 1). Thus
a totally new method for obtaining transgenic mice
was born, considerably widening the possibility of
‘‘classical’’ transgenesis by microinjection of DNA
in the zygote. Indeed, it became possible for the
investigator to use procedures selecting rare genetic
modifications in the ES cells and to obtain the cor-
responding mutant mice.
HOMOLOGOUS RECOMBINATION IN ES CELLS:
CREATION OF ‘‘KNOCK OUT’’ MICE
Studies conducted in the eighties, particularly by the
groups of Smithies and Capecchi, had demonstrated
that mammalian cells have the enzymatic apparatus
necessary for recombination between an incoming
DNA and the homologous sequence present in situ
in the chromosomes, even if this was relatively rare
compared with the random integration of this same
DNA (Smithies et al. 1985, Wong and Capecchi
1986). At first, these results were used by these
authors to create – or correct – null mutations in
thehprt gene (Doetschman et al. 1987, Thomas and
Capecchi 1987): these mutations can be selected di-
rectly after transfection of the targeted vector carry-
ing the required mutation, through addition of drugs
in the culture medium. Despite the generally vari-
able and low frequency of homologous recombina-
tion events, these experiments were later extended
to genes the null mutations of which cannot be se-
lected, using various approaches based either on se-
lection or on screening techniques (see Fig. 2). To-
day, hundreds of genes have been invalidated in this
manner and corresponding mutant mice have been
created (Tbase 2001). Analysis of the phenotypes
generated by these mutations has cast light on the
function of the genes concerned. In certain cases,
analysis also allowed to reveal the influence of ge-
netic background on the expression of a given mu-
tation (for a review, see Banbury Conference 1997),
or to investigate the eventual genetic relationships
between genes of the same family (for reviews, see
Rudnicki and Jaenisch 1995, Horan et al. 1995).
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TABLE I
A few milestones in the history of programmed mutagenesis in vivo in the mouse.*
1976** Transgenic mice by retroviral infection of embryos
during cleavage.
1980-1981** Transgenic mice by microinjection of DNA in the
pronucleus of the zygote.
1981 Establishment of ES cell lines.
1986 Transgenic mice via the generation of germline
chimeras with genetically modified ES cells.
1987 First experience of programmed mutagenesis:
ES cells carrying a null mutation in the HPRT gene
are obtained.
1989 First mutant mice obtained by homologous
recombination in ES cells.
1994 till today Creation of chromosomal rearrangements. Creation of
conditional mutations.
*Readers interested in the studies surrounding this history can consult the special
issue of the International Journal of Developmental Biology (vol. 42(7), 1998) for
the appropriate references. ** These transgenic mice result from gene addition
(microinjection of DNA in the zygote pronucleus and retroviral infection of cleav-
age stage embryos) and are not the subject of this paper. Interested readers can
consult the bookTransgenic Animals: generation and use, edited by Louis-Marie
Houdebine, Harwood Academic Publishers, 1997.
TABLE II
Mouse Embryonic Stem cells.
1. Properties
• Pluripotent
• Unlimited self-renewal in vitro with maintenance of the pluripotency.
Selection of rare genetic modifications possible.
• Differentiation in vitro into different cell types
• Colonization of the tissues of a host embryo including its germ line.
Transfer to the animal of the genetic modifications introduced
in the ES cells
2. Modifications created by homologous recombination
• Null mutations (knock-out)
• Subtle mutations (point mutations, microdeletions, microadditions, etc)
• Chromosomal rearrangements (deletions, inversions, translocations)
• Conditional mutations
AABC 73 3 b 3
An. Acad. Bras. Cienc., (2001)73 (3)
368 CHARLES BABINET and MICHEL COHEN-TANNOUDJI
Fig. 1 – The different stages in the creation of genetically modified mice via ES cells.
A REFINEMENT OF THE KNOCK-OUT: THE .....
KNOCK-IN
An interesting variation of the targeting vectors for
obtaining null mutations can be obtained by the in-
troduction of a given cDNA in frame with the coding
sequence of the targeted gene, (Fig. 2). Following
homologous recombination with the chosen target
gene, the modified allele expresses the cDNA in-
serted in replacement of the endogenous gene. The
choice of the cDNA obviously depends on the aim
of the research. For example, this might be the cod-
ing sequence of a reporter gene such asE. coli LacZ
gene encodingβ-galactosidase, the activity of which
is easily traceable even at the single cell level. The
expression ofβ-galactosidase mimics the expres-
sion of the targeted gene. This is precious for spec-
ifying its expression pattern (Colucci-Guyon et al.
1994), but can also be useful for monitoring the fate
of cells that normally express the targeted gene, in
the context of an animal carrying the mutation in
An. Acad. Bras. Cienc., (2001)73 (3)
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Fig. 2 – General principle of homologous recombination. a) ‘‘Knock-out’’. The targeting vector includes a selection cassette inserted in
an exon (black rectangle: coding region; white rectangles: non coding regions) and surrounded by regions of homology with the target
gene. Recombination with the endogenous gene occurs within these homologous sequences and results in the creation of a null allele
in which disruption of the gene is induced by insertion of the selection cassette. b) ‘‘Knock-in’’. In this variant, besides invalidation
of the target gene, a gene of interest is introduced in the locus. Following homologous recombination, the gene of interest is placed
under the control of the promoter and regulatory sequences of the target gene and is therefore expressed in place of the target gene.
the homozygous state (Schneider-Maunoury et al.
1993, Tajbakhsh et al. 1996). Another particularly
interesting use of the knock-in strategy concerns the
genes belonging to a multigenic family, with dif-
fering expression patterns, and the invalidation of
which leads to contrasting phenotypes. Do the pro-
teins coded by the related genes have equivalent
function? A positive reply to this would indicate
that the change in expression profile is at the origin
of the phenotypes observed and not a differing func-
tion of the proteins coded by these genes. According
to studies published to date (Table III and Hanks et
al. 1995, 1998, Wang and Jaenisch 1997, Saga 1998,
Acampora et al. 1999, Geng et al. 1999, Suda et al.
1999), it is generally this type of situation that is ob-
served, which underlines the importance of the gene
regulating regions acting as targets for evolution and
functional diversification.
FROM NULL TO SUBTLE MUTATIONS
If null mutations are a potent instrument in genetic
analysis, it is clear that other more subtle types of
mutations (point mutations, small deletions or in-
sertions) may also be very useful. On the one hand,
they allow to refine the functional analysis of a gene
(by changing the amino acid in a particular domain
of the protein and observing the effects induced, for
example) and on the other hand they also permit cre-
ation of murine models of genetic diseases in man:
the latter are rarely generated by null mutations (for
example, 60% of mutations leading to cystic fibro-
sis in man are ofF 508 type (Kerem et al. 1989),
i.e., corresponding to the deletion of a single amino
acid, phenylalanine, in the CFTR (Cystic Fibrosis
Transmembrane Receptor) protein. When mutant
alleles of this type are created, it is essential to re-
move the selection sequences that might interfere
with the regulation of the expression of the targeted
gene or adjacent gene. Such an interference has
been demonstrated in several studies (Fiering et al.
1999) and, in some cases can lead to hypomorph mu-
tations by the introduction the selection sequence in
the 5’ region of a gene (Meyers et al. 1998). Several
strategies can be used to create what one could call
‘‘clean’’ mutations (mutant allele without foreign
sequences) (Moore et al. 1998, for a review see
Cohen-Tannoudji and Babinet 1998). We describe
two of these in Figure 3; however, the one which
uses the Cre/loxP system is particularly interest-
ing, because, as we will see, it is versatile over and
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TABLE III
Some examples of knock-in.
Gene inserted→ gene disrupted Knock-out phenotype Knock-in phenotype Ref.
Cyclin E→ Cyclin D1 Neurological defects Complete restoration of Gent et al.
(Proteins implicated in cell Abnormalities of the a normal phenotype 1999
cycle control) retina and mammary
tissue
Otx2→ Otx1 Epilepsy Suppression of epilepsy Suda et al.
(homeodomain transcription Dorsal telencephalic and defects of 1999
factors) cortex and vision and corticogenesis but
audition system internal ear abnormalities
abnormalities maintained
Otx1→ Otx2 Abnormal gastrulation Gastrulation normal Acampora et
At E6, absence of Forelimb structures al. 1999
forelimb structure normal at E7-E8, but
loss of regionalisation of
structures before E9*
Myogenin→ Myf5 Malformation of the Complete restoration of Wang and
(transcription factors thorax a normal phenotype Jaenisch 1997
implicated in myogenic Prenatal lethality
differentiation)
Mesp1→ Mesp2 Prenatal death Complete restoration of Saga 1998
(b-HLH type transcription Absence of somatic a normal phenotype
factor) segmentation
Skeletal defects
En2→ En1 Prenatal death Disappearance of brain Hanks et al.
(homeodomain transcription Absence of defects but maintenance 1995
factor) posterior/mid-brain of the limb Hanks et al.
region abnormalities 1998
Limb abnormalities
*This loss is due to the fact that the OTX2 protein appears necessary for the regulation of the expression of
the otx2 gene. InOtx1→Otx2 mutants, theotx2 gene (and therefore the production of the OTX1 protein)
is not induced in the anterior neural plaque. E: day of embryonic development.
above obtaining ‘‘clean’’ mutations (for a review,
see Sauer 1998). The Cre protein is a recombi-
nase identified in the P1 bacteriophage, which re-
acts when it recognizes a sequence of 34 base pairs
(called loxP) in a segment of DNA (Kilby et al.
1993) (see Fig. 4A-B). When twoloxP sites are
oriented in the same direction, the Cre recombinase
induces the deletion of the DNA segment placed be-
tween them. Conversely, if theloxP sites are ori-
ented in opposite direction, recombination induces
its inversion (see Fig. 4C). It should be noted that
Cre recombinase activity does not require a DNA co-
An. Acad. Bras. Cienc., (2001)73 (3)
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Fig. 3 – ‘‘Clean’’ mutations. The persistence in a modified allele of a selection cassette with its own promoter and regulatory sequences
may affect the target locus and surrounding loci. Creation of subtle mutations (point mutations, small deletions and insertions, ...)
therefore requires elimination of the selection cassette. The two strategies most used to create this type of modifications are presented
in this figure. Upper panels: the double replacement strategy. This approach requires the use ofhprt-ES cell lines. The first step
(A) consists in introducing a cassette expressing thehprt gene in the target gene. The recombinant cells (hprt+) are selected in the
presence of HAT. In the second step (B), these cells are transfected with a replacement vector presenting a subtle mutation and devoid
of a selection cassette. The homologous recombination event results in the loss of thehprt expression cassette, an event selected in the
presence of 6-TG. The use of other replacement vectors carrying different modifications permits the rapid creation of several alleles
for the same target gene. Lower panels: use of the Cre/loxP system (see Fig. 4). In the first step (C), the target gene is modified by a
target vector with a subtle mutation and a ‘‘floxed’’ selection cassette, i.e. surrounded by 2loxP sites in the same orientation. Then (D)
the transient expression of Cre recombinase in the recombinant cells induces deletion of the selection cassette. Apart from the desired
subtle modification, only oneloxP site of 34 pb persists in the final modified allele. The position of thisloxP site is chosen so that it
does not interfere with the expression of the target gene (generally in an intron).
factor or particular topology. Moreover, it is active
in the eukaryote cells (Sauer and Henderson 1988).
As is shown in Figure 3, these properties of the Cre/
loxP system could be used for the creation of alle-
les carrying ‘‘subtle’’ and ‘‘clean’’ mutations. At
the end of this scenario, the muted allele retains a
loxP site; however, no indication of an interference
of this site with genetic expression has ever been
demonstrated.
DELETIONS VIA TARGETING IN THE ES CELLS:
TOWARDS GLOBAL GENETIC ANALYSIS OF THE
MOUSE GENOME
Directed mutagenesis via ES cells is, as we have
seen, a precious method for analysis of gene func-
tion. However this approach is limited to known and
cloned genes. In a perspective of global functional
analysis of the mouse genome, this inverse genetic
approach must be completed by strategies that not
AABC 73 3 b 3
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only accumulate mutations but also localize them
precisely. Thus corresponding genes can eventually
be identified and cloned and then be used for targeted
mutagenesis.
Over the past fifteen years, highly effec-
tive methods of chemical mutagenesis have been ob-
tained which result in high-rate and random intro-
duction of mutations in the mouse genome: the use
of N-ethyl-N-nitrosourea (ENU) (Bode 1984), for a
review, see Brown and Peters 1996), a potent muta-
genic agent, leads, in the male mouse, to a mutation
in a given gene in one gamete out of 700 (which
is equivalent to a per locus mutation of around 1.5
x 10-3 and is very high). In general, the effect of
ENU results in the creation of point mutations. Once
the males have been treated by ENU and therefore
carry mutations in their spermatogonia, an approach
is needed to identify and collect these mutations.
This would be made easier, in the case of reces-
sive mutations, if one disposed of discrete deletions
throughout the genome: the crossing between mice
carrying a deletion in a given region and those car-
rying mutations induced by ENU should facilitate,
the localization and the identification of the gene(s)
responsible for the phenotype obtained, due to func-
tional haploidy of the deleted region. This type
of scenario, the interest of which has been clearly
demonstrated in Drosophila, is difficult to apply to
the mouse because of the relative rarity of deletions
reported in this animal. In this context, targeting by
homologous recombination in ES cells combined
with the properties of the Cre/loxP system opens
new opportunities ( for a review, see Justice et al.
1997) (Fig. 4C-D). This strategy was validated in
1995 when mice carrying deletions of several cen-
timorgans (cM) were obtained (Ramirez-Solis et al.
1995). Using a different scenario, You et al. (1997)
obtained deletions of varying length around a given
locus. In the future, a collection of deletions could
be accumulated and used, in combination with ENU
mutagenesis, for long-term projects of global func-
tional analysis of the mouse genome. The constant
extension of genetic maps of the mouse and man
should permit to analyse more specifically genomic
regions which would be rich in genes and/or thought
to be candidates for human genetic diseases.
CHROMOSOMAL REARRANGEMENTS MADE
EASIER BY THE EXPRESSION OF CRE IN THE MALE
GERM LINE
The recent generation of transgenic mice expressing
Cre in the male germ line has simplified the process
permitting the creation of chromosomal rearrange-
ments in the mouse, by conducting part of the op-
erations directly in vivo. Indeed, transgenic mice
with anSycp1-Cre fusion gene (in which the regula-
tory sequences ofSypc1 coding for protein 1 of the
synaptosomal complex control Cre protein expres-
sion), express the Cre protein in a specific manner
during the pro-phase of the first meiotic division of
male germ line cells, at a time when the chromoso-
mal pairing starts and crossing-over is therefore fa-
cilitated (Vidal et al. 1998). If one crosses mice car-
rying loxP sites on chromosomes homologous with
the latter, one obtains, in double-transgenic males
issued from this crossing, spermatozoa containing
deletions or duplications of the genomic region situ-
ated between theloxP sites (Figure 4D). Potentially,
this approach is a strong tool for the functional anal-
ysis of complex genomic regions: for example, the
question of functional significance of the clustering
of Hox genes into complexes can be determined by
varying their number or their position in these com-
plexes (Herault et al. 1998).
CONDITIONAL MUTAGENESIS: A NEW DIMENSION
OF FUNCTIONAL GENOME ANALYSIS
a) The Cre/loxP system: targeting of Cre by
a fusion transgene
We have emphasized the interest for the functional
analysis of the genome of programmed creation of
mice carrying various genetic modifications (null
mutations, discrete mutations, chromosomal rear-
rangements, etc). However, these situations in
which mutated mice carry the mutation in all their
cells have their limitations in particular for two rea-
sons: (1) in cases in which the mutation provokes
embryonic lethality in the homozygous state (an ex-
An. Acad. Bras. Cienc., (2001)73 (3)
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treme case is when mutation leads to cell death), it
is impossible to study the eventual function of the
gene beyond the time of embryonic letality and con-
sequently during adulthood; (2) a gene may have a
wide expression and its invalidation provoke a com-
plex phenotype affecting multiple tissues. To sim-
plify analysis in this case it would be interesting to
create mice expressing the mutation in only one or
the other of these tissues.
In an effort to overcome these limitations of
programmed mutagenesis in vivo, in recent years
different teams tried to develop strategies in which
the expression of a mutation would be rendered con-
ditional (for a review, see Gu et al. 1994, Cohen-
Tannoudji and Babinet 1998). These strategies are
based on the remarkable properties of theCr /loxP
system. The first step (see Fig. 5) consists in cre-
ating mice carrying alleles in which twol xP sites
surround an essential part of the gene to be studied,
without disrupting its activity, by placing them for
example in the introns (we subsequently call these
alleles ‘‘floxed’’ alleles). In the case of a gene whose
null mutations are letal in the homozygous state, it
is necesssary to verify that the mice homozygous
for the floxed allele are viable. These mice are then
crossed with a transgenic mouse expressing the Cre
recombinase in a particular cell type, using appro-
priate regulatory sequences in the transgene (the Cre
recombinase promotes the deletion of the sequences
located between theloxP sites and induces a null
mutation in the cell type in which the transgene is
expressed). This strategy is powerful since it not
only avoids the embryonic lethality produced when
all the embryo cells carry the mutation, but also al-
lows to address the effect of this mutation in any
tissue, so long as a line of transgenic mice express-
ing protein Cre in the tissue concerned is available
(Table IV, Tsien et al. 1996, Shibata et al. 1997,
Harada et al. 1999, Kulkarni et al. 1999, Xu et al.
1999).
b) Inducible systems
Supplementary refinement consists in controlling in-
duction of the mutation, not only in space as ex-
plained above but also in time. To that end„ pro-
tein Cre is expressed in the form of a fusion protein
with the ligand binding domain of a steroid receptor
(LBD) (Kellendonk et al. 1996, Feil et al. 1996);
this fusion protein has no Cre activity (see Fig. 6).
However, in the presence of an appropriate ligand, a
change in conformation is produced that restores Cre
activity. Thus, in transgenic mice carrying the two
floxed alleles of the gene concerned and the trans-
gene expressing the fusion protein LBD/Cre under
the control a promoter functioning in a given tissue,
induction of a null mutation can be obtained by injec-
tion, at a given time, of the appropriate ligand (Fig.
6). An interesting alternative to the use of LBD/Cre
fusion proteins was recently demonstrated by the in-
jection, in a tissue of a mouse carrying the ‘‘floxed’’
gene, of an adenoviral vector capable of expressing
Cre: indeed, only the cells infected locally by the
virus expressed the mutation (Table IV and Shibata
et al. 1997). To end our brief description of the
approaches developed to obtain conditional muta-
tions, one must mention the possibility of control-
ling the recombinase expression by using systems
that induce or inhibit the transcription of a reporter
gene. The most documented system uses the op-
rator/repressor properties of the bacterial operon,
tetracycline (tet) (Baron et al. 1999). This com-
prises on the one hand a reporter gene controlled by
a minimal promoter linked to a concatermer of the
tet operator(tetO) sequences, and on the other hand a
gene expressing a fusion protein between the repres-
sor tetR and the activation domain of the VP16 pro-
tein (protein tTA). In the presence of tetracycline the
fusion protein cannot bind to thet tO sequences and
the reporter gene is not expressed. In the absence
of tetracycline, the fusion protein can bind and the
reporter gene is expressed. An alternative is to use a
fusion protein constructed with a mutant version of
the tetR repressor which can only bind to theetO
sequences in the presence of tetracycline: activation
of the reporter gene can therefore be induced by ad-
dition of the antibiotic. The proof of the transcrip-
tional control obtained using this binary system has
been demonstrated in cell cultures and in transgenic
AABC 73 3 b 3
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Fig. 4 – The Cre/loxP system and its applications. TheloxP site, symbolized by a triangle is a sequence of 34 base pairs composed of
palindromic sequences of 13 pb separated by a sequence of 8 pb (A). Cre recombinase specifically recognizes this sequence, provokes
the cleavage in DNA (vertical arrows, A) and induces the recombination of DNA between the twoloxP sites as illustrated in B. This
reaction is reversible. Several types of recombination events can be produced depending on whether the twoloxP sites are carried by
the same DNA molecule (recombination in cis) or by two different DNA molecules (recombination in trans) and depending on the
respective orientation of the twol xP sites (the orientation of aloxP is given by the non-palindromic 8 pb sequence). Recombination
in cis (C). If the twoloxP sites have the same orientation, the DNA region situated between these sites is deleted during recombination.
This type of configuration is used to create ‘‘clean’’ mutations (elimination of the selection cassette, see Fig. 3), conditional mutations
(see Fig. 5) and deletions. If the orientation of the twoloxP sites is opposed, recombination leads to the inversion of the region
comprised between the two sites. Recombination in trans (D). If onel xP site is integrated in the genome and the other is carried
by a circular plasmid, there may be an insertion of sequences carried by the plasmid in the integratedloxP site. However, since
the insertion is a rare event compared to deletion (i.e., the reverse reaction), this type of event requires the use of mutantl xP si es
(see Conclusions/Perspectives). When theloxP sites are both integrated in the genome, recombination in trans induces chromosomal
rearrangements: deletions, duplications or translocations. Such recombination events are rare and have to be selected to be revealed.
To do so, one can use truncated and non-functional hp-loxP andloxP-rt selection cassettes. After recombination between theloxP sites,
and only in this case, a functional hp-loxP-rt cassette (the remainingloxP site is situated in an intron) is reconstituted, thus allowing
selection of the chromosomal rearrangement desired. Furthermore, the relative orientation ofloxP sites compared with the centromeric
telomeric axis of the chromosomes is important. Indeed, in the case of wrong relative orientation, recombination will result in the
formation of acentric or dicentric chromosomes, which, in view of their great instability, will be eliminated from the cell.
mice. This strategy could therefore be used for the
temporal and spatial control of the expression of Cre
(Utomo et al. 1999). For various reasons, the con-
ditional mutagenesis strategies that we have briefly
described may prove difficult to use. However they
are of invaluable interest in thorough gene function
analysis and many teams are conducting research
to improve the different steps. Two conditions are
mandatory to avoid any bias in results and their inter-
pretation: (1) the total cell population in which one
wants to measure the impact of the mutation must
express protein Cre; (2) expression of protein Cre
must be strictly controlled and limited to the popu-
lation concerned. These conditions are difficult to
fulfill, in particular because expression of protein
Cre is generally obtained by the creation of conven-
tional transgenic mice (through microinjection into
the zygote) in which the transgene is integrated at
random; however, it is well established that trans-
gene expression depends on its site of insertion and
therefore may be perturbed or even lost. This can
be circumvented by inserting, via ‘‘Knock-in’’ (see
above), Cre coding sequences in a gene with spe-
cific expression corresponding to the cell types in
which the investigator wishes to induce the muta-
tion (Rickert et al. 1997, Harada et al. 1999).
CONCLUSION/PERSPECTIVES
If we look at the present state of programmed mu-
tagenesis in vivo in the mouse, several reflections
come to mind as regards the ways to circumvent the
present difficulties and the possible developments.
1) First, it is important to note that among the
mammalians studied, programmed modification of
the germ line is only accessible in laboratory mice.
Indeed, until now, it has been impossible, despite
multiple attempts, to isolate ES type cells capable of
colonizing the germ line in other laboratory or farm
mammals. A special mention should be made about
the human species. Indeed, three different groups
(Thomson et al. 1998, Shamblott et al. 1998, Reubi-
noff et al. 2000) have recently reported the isolation
of human pluripotent embryonic stem cells. In two
cases, these cells were isolated from blastocysts,
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Fig. 5 – The Cre/loxP system in vivo. The Cre/loxP system can be used directly in the mouse. The most common applications of this
approach are illustrated in this figure and require the use of two types of mouse. The first mouse (line A), obtained after homologous
recombination in the ES cells, carries in its genome a ‘‘floxed’’ sequence (exons, regulatory sequences, promoter, selection cassette,...).
The other is a transgenic mouse expressing the Cre recombination under the control of a given promoter. If this promoter directs the
expression of Cre in the female germ line (strain C), the animals issued from a cross between a female C and a male A will carry the
deletion in all their cells, the recombination event having taken place at the zygote stage through the recombinase accumulated in the
oocyte. If the promoter directs the expression of Cre in one or several cell types (strain B), the animals born from a cross between a
mouse A and a mouse C will be mosaics: the cell types expressing the recombinase will carry a deleted allele whereas the other cells
of the animal will carry a ‘‘floxed’’ allele. CNS: central nervous system; P: promoter.
in the third case, the pluripotent cells were gener-
ated taking a different route in which germ cells
from foetal gonads were used as a starting material
(these cells are therefore called Embryonic Germ
(EG) cells). Although it was not possible to test
their ability to contribute to the germ line, the hu-
man ES cells share with those of the mouse other
key features of embryonic stem cells, i.e., unlimited
self-renewal, normal caryotype, ability to differenti-
ate into cell types of the three germ layers. However,
there remain several problems to be solved before
they can be used in such a versatile way as is the
case with mouse ES cells. These difficulties per-
tain, in particular, to the very limited knowledge of
the factor(s) which control and maintain the undif-
ferentiated state and to the fact that they exhibit a
poor ability to grow clonally. Despite these limita-
tions, which should be overcome in the near future,
the availability of human ES cells opens new and
very interesting possibilities both for a better under-
standing of human embryonic development and for
ES cell based therapies (for a review, see Pera et al.
2000).
A recent study illustrates a possible means,
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TABLE IV
Some examples of knock-in.
Target Null mutation Cre targeting Tissues eliciting Conditional Ref.
gene phenotype method recombination mutation
phenotype
APC Embryo death Infection by Colorectal Intestinal polyps Shibata
(E 6.5) adenovirus epithelium et al.
(inoculation site) 1997
β-catenine Embryo death Knock-in Intestinal Intestinal polyps Harada
(E 7.5) (Ktr1-19) or epithelium et al.
Tg (Fabp) 1999
IR (insulin Diabetic acid Tg (Ins) β cells of the Type II diabetes Kulkarni
receptor) ketosis pancreas et al.
Perinatal lethality 1999
BRCA1 Embryo death Tg (WAP) Epithelium of the Tumors and Xu et al.
(E 8.5) mammary gland abnormal 1999
development of
the breast gland
NMDAR1 Prenatal lethality Tg Hippocampus Spatial memory Tsien et
Multiple CNS (αCAMKII) (pyramidal cells acquisition al. 1996
abnormalities of the CA1 defects
region)
Tg: transgenic mouse for a fusion gene between the coding sequences of Cre recombination and the regulatory
sequences (including the promoter) of the genes indicated (Fabp: fatty acid binding protein; Wap: whey
acidic protein;αCa MKII: ( calcium calmoduline kinase II dependent); Krt1-19:cytokeratine 19; CNS:
central nervous system.
though experimentally demanding, to perform pro-
grammed genetic modifications in absence of bona
fide ES cells; it is based on the advent of methods al-
lowing cloning of several mammalian species by the
transfer of nuclei from embryonic and even adult nu-
clei into oocytes (sheep, cow, mouse and and most
recently pig) (for a review, see (Solter 2000). In-
deed, McCreath et al. (2000) targeted the ovineα1
(I) procollagen gene in sheep fetal fibroblasts and
could reconstitute a whole animal by the transfer
of a nucleus carrying the genetic modification into
an enucleated oocyte. Despite its fairly low rate
of success (about 1% of the reconstructed embryos
give rise to live and apparently normal offspring),
these results represent a breakthrough and demon-
strate the feasability of obtaining gene targeted ani-
mals in mammals by nuclear transfer.
2) We have emphasized the obvious interest
of obtaining, via programmed ES cell mutagenesis,
mutants for the study of various biological prob-
lems. However two other aspects of ES cells should
be underlined. The first pertains to the ability of
ES cells to undergo differentiation in vitro. Over
recent years, a number of teams have tried to de-
velop experimental conditions permitting orienta-
tion of this differentiation towards a given lineage
(muscle, hematopoietic, nerve cells, etc.) (Brustle et
al. 1999, for a review see Keller 1995). Once these
AABC 73 3 b 3
An. Acad. Bras. Cienc., (2001)73 (3)
378 CHARLES BABINET and MICHEL COHEN-TANNOUDJI
Fig. 6 – The Cre/loxP system and inducible mutations. (A) This strategy relies on the use of a fusion protein between the Cre
recombinase and the ligand binding domain of a steroid hormone nuclear receptor. In the absence of a ligand, recombinase activity
is null or very weak, whereas in the presence of a ligand it is rapidly induced. The ligand-binding domain is a modified version
which presents reduced affinity for the natural ligand (progesterone, estrogen) but increased in the case of synthetic analogs (RU486,
tamoxifen). The activity of this inducible Cre recombinase (Cre-ind) is therefore controlled by administration of the agonist. b) This
strategy can be applied in vivo, in animals carrying not only a ‘‘floxed’’ sequence but also a transgene coding for Cre-ind controlled
by a promoter (ubiquitous here). Deletion of the ‘‘floxed’’ sequence is dependent on the administration to this mouse of an agonist. It
therefore provides a way to control the time of the appearance of a targeted genetic modification. If, instead of an ubiquitous promoter,
a specific promoter is used, then the appearance of the modification can be controlled both in terms of time and localization (tissue or
cell type).
systems have been developed, introduction in ES
cells of the gene mutations eventually implied in a
given differentiation pathway and should bring new
light on their function. Secondly, certain aspects of
the phenotype engendered by a given genetic modifi-
cation (null mutation in the homozygous state, dom-
inant negative allele) can be further defined by the
creation of chimeras between the genetically mod-
ified ES cells and wildtype embryos (Rossant et al.
1998). This type of analysis allows, in particular, to
determine whether a mutation is cell autonomous or
not.
3) From a methodological point of view, de-
spite the wide use of programmed mutagenesis in
the mouse, it should be noted that it remains diffi-
cult and expensive not only in time but also in terms
of budget. From this point of view, the development
of new scenarios should in the long-term ensure that
the creation of mutations is less costly and more ef-
ficient. These scenarios profit essentially from the
existence of enzymatic systems that play a role in the
recombination process. One of them is the Cre/loxP
system that has been largely presented above. Thus,
it would be valuable to try and take advantage of
the integration event catalyzed by the Cre recombi-
nase, resulting in the integration of a circular DNA
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carrying aloxP site in a genomic location of inter-
est also carrying aloxP site (Fig. 4D). Normally
it is the reverse reaction (intramolecular deletion)
that is privileged. However some ‘‘tricks’’ (based
on the use of mutantloxP sites) allow to enhance
the insertion reaction (Araki et al. 1997). Another
approach relies on the observation of robust stim-
ulation of recombination following double-strands
DNA breaks. These can be promoted by using a
meganuclease, I-SceI, isolated from yeast, which
recognizes a specific 18 bp site. Once an allele of a
given gene carrying an I-SceI site has been created
(by homologous recombination in ES cells), varying
genetic modifications could be introduced repeat-
edly and efficiently by co-transfection of an expres-
sion vector for I-SceI, promoting a double-strand
break, together with a repair vector permitting the
introduction of the desired modification (Donoho et
al. 1998, Cohen-Tannoudji et al. 1998). Such ap-
proaches may ultimately permit programmed muta-
genesis directly in ovo, which would represent an
obvious simplification.
4) Despite the interest of targeted mutagenesis
that we have underlined in this article, it remains a
quite laborious and step by step process: cloning
of the gene considered, construction of appropriate
vectors, selection and identification of targeted cells
and derivation of the corresponding mutant mice.
More than 1500 genes have now been processed in
this manner, which is a minority compared with the
30 to 40 000 genes contained by the genome of the
mouse or man. Sequencing programs will provide
these genes, till we reach complete sequencing of the
mouse genome which should soon happen. There
would be great interest in developing tools permit-
ting the mutation of any gene, while circumventing
the cloning phase. As far as this is concerned, an
approach is being developed, based on a gene trap
strategy strategy in ES cells using a trapping vector
which in principle traps any gene, whether expressed
or not (Zambrowicz et al. 1998).Thus, a library of
ES cells is available, carrying tagged genes. How-
ever, this approach has its own limitations: the type
of mutation is stereotyped (insertion) and insertion
of the trapping vector does not lead to total inval-
idation in all cases. In conclusion, it is clear that
homologous recombination in ES cells of the mouse
has met its expectations. Creation of widely varying
types of mutations, affecting either a gene or whole
genomic regions continues to supply invaluable in-
formation on the function of genes and the genome
in the physiology and biology of the mouse while
providing murine models of human diseases. The
recent methodological developments, based on the
use of proteins that intervene in the recombination
process, will obviously widen these possibilities not
only qualitatively but also quantitatively.
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RESUMO
A capacidade de introduzir modificações genéticas na li-
nhagem germinal de organismos complexos tem sido, por
muito tempo, uma meta dos estudiosos da biologia do
desenvolvimento. Neste aspecto, o camundongo, um mo-
delo favorito de estudo dos mamíferos, é singular. Assim,
desde o final dos anos setenta, tem sido possível não só
adicionar genes ao genoma do camundongo, como em
vários outros organismos complexos, mas, também rea-
lizar a substituição e modificação de seus genes. Isto tem
sido possível graças a dois rasgos tecnológicos: 1) o iso-
lamento e cultura de células-tronco embrionárias, que
têm a capacidade singular de colonizar todos os tecidos
de um embrião hospedeiro, inclusive de sua linhagem ger-
minal; 2) o desenvolvimento de métodos que permitem a
recombinação homóloga entre um DNA que ‘‘ingressa’’
e sua seqüência cromossomal cognata (‘‘mira’’ genética
– ‘‘gene targetting’’ Como resultado, tornou-se possível
criar camundongos que carreiam mutações nulas em qual-
quer gene clonado (camundongos ‘‘knock out’’). Tal pos-
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sibilidade revolucionou a abordagem genética de quase
todos os aspectos da biologia do camundongo. Em anos
recentes, o escopo da ‘‘mira’’ genética ampliou-se ainda
mais devido ao refinamento da tecnologia de ‘‘knock
out’’: outros tipos de modificações genéticas podem agora
ser criadas, incluindo mutações sutis (mutações puncti-
formes, micro-deleções ou inserções, etc) e rearranjos
cromossomais tais como grandes deleções, duplicações
e translocações. Finalmente, têm sido implementados
métodos que permitem a criação de mutações condicio-
nais, permitindo o estudo da função gênica ao longo da
vida do animal, quando a inativação do gene acarreta a
letalidade embrionária. Neste artigo, apresentamos uma
revisão geral dos métodos e situações usadas para a modi-
ficação programada do genoma do camundongo e acentu-
amos seu enorme interesse para o estudo da biologia dos
mamíferos.
Palavras-chave: células-tronco embrionárias, genoma,
mira genética, camundongos ‘‘knock out’’, mutações con-
dicionais.
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